Mylor Bio Shines at TPE 2025: Pioneering New Heights in E-Liquid Technology

Feb.13.2025
From January 29th to 31st, one of the world’s largest tobacco and e-cigarette trade shows, the Total Product Expo (TPE), took place in Las Vegas. Mylor bio Co.,Ltd (hereafter referred to as “Mylor Bio”) made its mark at the event, showcasing its FUNC series nicotine salts and flavor modification technologies, offering groundbreaking solutions to push the boundaries of e-cigarette technology.

[2Firsts Reporting from Las Vegas] From January 29th to 31st, one of the world’s largest tobacco and e-cigarette trade shows, the Total Product Expo (TPE), took place in Las Vegas. As a platform for technological innovation in the e-cigarette industry, TPE gathers global brands, distributors, and experts, serving as a crucial venue for product launches and technical discussions. Mylor bio Co.,Ltd (hereafter referred to as “Mylor Bio”) made its mark at the event, showcasing its FUNC series nicotine salts and flavor modification technologies, offering groundbreaking solutions to push the boundaries of e-cigarette technology.

 

About Mylor Bio:

 

Mylor bio Co.,Ltd., a global leader in the development and manufacturing of e-liquid products, was founded in 2019. With state-of-the-art automated production lines and stringent quality control systems, Mylor Bio has rapidly established itself as an industry benchmark. The company operates a modern 5,000 square meter manufacturing facility, achieving an automation rate of 80%. Well-equipped with cutting-edge analysis instruments, such as GC, GC-MS, HPLC, and ICP-MS.With the support of a professional R&D team consisting of over ten experienced flavorists, Mylor Bio has successfully developed over 30,000 e-liquid formulas. The products are exported to key global markets including Europe, North America, the Middle East, Southeast Asia, and Russia.

 

Mylor Bio Shines at TPE 2025: Pioneering New Heights in E-Liquid Technology
Mylor Bio Certification | Image Source: Mylor Bio

 

In the future, Mylor Bio will become an innovative pioneer in the industry through continuous technological advancements and an open collaboration approach, with a more forward-thinking vision and scientific practices.

 

FUNC Series Nicotine Salts: Precision Sensory Delivery  and Personalized Experience

 

Nicotine is the primary active ingredient in e-cigarettes, with the majority of it remaining in the aerosol as nicotine salts.. Nicotine salts are smoother and less harsh, allowing for a higher inhalable nicotine concentration.


Mylor Bio, drawing on years of customer service experience and market research, has recognized the diverse demands of different consumer groups regarding the sensation of nicotine. Leveraging the release patterns and absorption mechanisms of nicotine, Mylor Bio has innovatively launched the FUNC series nicotine salts to meet diverse needs.

 

Mylor Bio Shines at TPE 2025: Pioneering New Heights in E-Liquid Technology
FUNC Series Nicotine Salts Product at TPE Booth

 

Mylor Bio Shines at TPE 2025: Pioneering New Heights in E-Liquid Technology
FUNC Series Nicotine Salts Product at TPE Booth

 

FUNC Series Nicotine Salts Features:

 

· Precise Sensory Delivery: The FUNC series nicotine salts are designed to precisely target the head, throat, and chest areas, addressing a variety of preferences for headrush, throat hit, and chest kick sensations.

· Variety of Options: Including H-nicotine salt, T-nicotine salt, and C-nicotine salt.

 

Mylor Bio Shines at TPE 2025: Pioneering New Heights in E-Liquid Technology
Diagram showing the partitioned effects of FUNC series nicotine salts | Image Source: Mylor Bio

 

Mylor Bio Shines at TPE 2025: Pioneering New Heights in E-Liquid Technology
Sensory characteristics comparison between three nicotine salts and nicotine benzoate | Image Source: Mylor Bio

 

Compared to nicotine benzoate, H-nicotine salt's headrush intensity and onset speed increased by 43% and 25%, respectively; T-nicotine salt's throat hit improved by 43%; C-nicotine salt's chest kick increased by 67%.

 

Mylor Bio Shines at TPE 2025: Pioneering New Heights in E-Liquid Technology
Comparison of market appeal between three nicotine salts and nicotine benzoate | Image Source: Mylor Bio

 

Compared to nicotine benzoate, the consumer liking for H-nicotine salt, T-nicotine salt, and C-nicotine salt increased by 42%, 25%, and 46%, respectively. The willingness to use again increased by 66%, 25%, and 33%.

 

Flavor Modification Solutions: Improving E-Liquid Flavor Profile

 

Beyond nicotine salts, flavor profile is another key factor in consumer choice of e-cigarettes. At TPE, Mylor Bio showcased its flavor modifiers, including:

· Sweeteners: Enhancing the natural sweetness, customized for ceramic core devices.

· Acidulants: Maximizing the freshness of fruit flavors.

· Cooling Agents: Precisely regulating the cooling effect’s target areas.

· Humectants: Enhancing hydration sensation and smoothness

 

Mylor Bio: Reshaping the Future of the Industry through Technological Innovation

 

At this year’s TPE, Mylor Bio’s booth attracted many international buyers. Ms. Lin, Sales Manager of Mylor Bio, shared:
“During this exhibition, we presented our latest nicotine salt series products, which received high recognition from industry professionals. We have already reached initial cooperation intentions with several globally renowned brands.”

 

Mylor Bio Shines at TPE 2025: Pioneering New Heights in E-Liquid Technology
Visitors at the TPE exhibition show interest in Mylor Bio’s nicotine salt technology

 

Mylor Bio Shines at TPE 2025: Pioneering New Heights in E-Liquid Technology
Visitors at the TPE exhibition show interest in Mylor Bio’s nicotine salt technology

 

John, an e-cigarette brand owner from the United States, expressed, “Mylor Bio's nicotine salt technology is indeed impressive. The innovations in taste are refreshing, especially the precise nicotine delivery technology combined with multiple flavor modification solutions which have broken new ground in flavor details. This multi-layered sensory experience is exactly what the market needs.”

 

 

GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
The Global State of Tobacco Harm Reduction, a project operated by Knowledge·Action·Change, estimates that about 200 million people worldwide use non-combustible nicotine products including vapes, heated tobacco, nicotine pouches and snus. Its 2026 report says use of these products rose alongside declining smoking rates in 28 countries it analyzed. The data do not establish that all 200 million users have quit smoking, nor do they prove a direct causal relationship. GSTHR also says regulatory restrictions on the products continue to expand in many markets.
Sep.10
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
EU Tobacco Tax Reform Targets November Push as Sweden Holds Nicotine-Pouch Minimum at €20 per Kilogram
EU Tobacco Tax Reform Targets November Push as Sweden Holds Nicotine-Pouch Minimum at €20 per Kilogram
The Irish presidency of the Council of the European Union is using bilateral talks to push the bloc’s Tobacco Taxation Directive toward a political agreement in November. According to Law360, citing an EU official, Sweden is unwilling to accept a minimum excise threshold above €20 per kilogram for nicotine pouches. Council negotiations have already lowered the European Commission’s original proposal, but a May 2026 presidency compromise still set the minimum at 10% of the tax-inclusive retail price or €30 per kilogram in 2028-29, with higher levels later.
Market
Sep.17 by 2Firsts Perspectives
Philip Morris Malaysia Again Meets Religious Authority Over Cigarette Alternatives as Perlis Mufti Responds on Halal Criteria
Philip Morris Malaysia Again Meets Religious Authority Over Cigarette Alternatives as Perlis Mufti Responds on Halal Criteria
Philip Morris Malaysia Managing Director Naeem Shahab Khan met Perlis Mufti Mohd Asri Zainul Abidin on September 17 and presented the company's shift from conventional cigarettes toward alternative products. The mufti said a product could be considered halal if it is clean, its side effects are not harmful or can be controlled, and it does not involve excessive waste. His remarks did not mention IQOS or any other specific PMI product and did not amount to a new product-specific religious ruling. It was at least the second publicly reported engagement between Philip Morris Malaysia and a Malaysian religious institution over cigarette alternatives within six months.
Regulations
Sep.18 by 2Firsts Perspectives